Jagsonpal Pharmaceuticals Limited Stock price

Equities

JAGSNPHARM

INE048B01027

Pharmaceuticals

Delayed NSE India S.E. 04:22:27 2024-03-28 am EDT 5-day change 1st Jan Change
281.8 INR +0.39% Intraday chart for Jagsonpal Pharmaceuticals Limited -0.69% -27.54%
Sales 2022 2.26B 27.12M Sales 2023 2.37B 28.39M Capitalization 7.59B 91.06M
Net income 2022 196M 2.35M Net income 2023 267M 3.2M EV / Sales 2022 3.42 x
Net cash position 2022 482M 5.78M Net cash position 2023 1.09B 13.03M EV / Sales 2023 2.75 x
P/E ratio 2022
41.9 x
P/E ratio 2023
28.4 x
Employees 940
Yield 2022
1.28%
Yield 2023
1.73%
Free-Float 22.13%
More Fundamentals * Assessed data
Dynamic Chart
Jagsonpal Pharmaceuticals Limited Launches Queezy-ER® CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1 MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar. CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm cancelled the acquisition of 26% stake in Jagsonpal Pharmaceuticals Limited. CI
More news
1 day+0.39%
1 week-0.69%
Current month-5.47%
1 month-6.94%
3 months-27.68%
6 months-32.32%
Current year-27.54%
More quotes
1 week
273.60
Extreme 273.6
295.00
1 month
273.60
Extreme 273.6
312.15
Current year
273.60
Extreme 273.6
412.00
1 year
273.60
Extreme 273.6
514.85
3 years
75.25
Extreme 75.25
514.85
5 years
16.25
Extreme 16.25
514.85
10 years
9.90
Extreme 9.9
514.85
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-07-15
Compliance Officer - 23-02-12
Director/Board Member 67 78-08-16
Members of the board TitleAgeSince
Director/Board Member 67 78-08-16
Chairman 52 22-06-28
Chief Executive Officer - 22-07-15
More insiders
Date Price Change Volume
24-03-28 281.8 +0.39% 14 916
24-03-27 280.7 +1.83% 47,600
24-03-26 275.6 -3.94% 60,785
24-03-22 287 +1.13% 20,320
24-03-21 283.8 -1.48% 17,959

Delayed Quote NSE India S.E., March 28, 2024 at 04:22 am EDT

More quotes
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Company’s therapy areas include gynecology, orthopedics, and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Jagsonpal Pharmaceuticals Limited - NSE India S.E.